In a first-in-human study, we found that repeated intrathecal (IT) administration of ION363 in a patient with ALS-FUS with a FUSP525L mutation results in the marked suppression of FUS expression in the brain and spinal cord and the reduction of the FUS aggregates that are the pathological hallmark of this disease. Here, FUS is linked to amyotrophic lateral sclerosis.